Emergent BioSolutions (NYSE:EBS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.
Plans to have a vaccine that limits methane emissions by angulates have been under way, through a pioneering collaboration between the Pirbright Institute and the Royal Veterinary College.
In addition to the CYFENDUS ® vaccine, Emergent’s anthrax franchise includes the BioThrax ® vaccine, which continues to serve a critical purpose, as well as two treatments, Anthrasil ® [Anthrax Immune ...